Von Willebrand factor in the plasma and in the tumor tissue predicts cancer-associated thrombosis and mortality
Open Access
- 22 September 2022
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 108 (1) , 261-266
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasisOncotarget, 2016
- von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humansBlood, 2015
- High D-dimer levels are associated with poor prognosis in cancer patientsHaematologica, 2012
- Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common CancersArchives of internal medicine (1960), 2006
- Plasma von Willebrand factor antigen levels in non-small cell lung cancer patients.2005
- Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 von Willebrand factor cleaving protease)Journal of Thrombosis and Haemostasis, 2003
- Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease).2003
- ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasisThrombosis Research, 2003
- Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patientsThrombosis Research, 2002
- Prognosis of Cancers Associated with Venous ThromboembolismNew England Journal of Medicine, 2000